FORXIGA AstraZeneca Pty Ltd
Product name
FORXIGA
Sponsor
Accepted date
Jan-2024
Active ingredients
dapagliflozin propanediol monohydrate
Proposed indication
To reduce the risk of progressive decline in kidney function in adults with proteinuric chronic kidney disease (CKD Stage 2, 3 or 4).
Application type
C (new indication)
Publication date
Jan-2024